Anti-proliferative activity on drug-sensitive and drug-resistant erythroleukemic cells of Samor Pipek (Terminalia bellirica (Gaertn.) Roxb.) fruit extracts
Article Sidebar
Main Article Content
Abstract
Introduction: Cancer is a major cause of death in Thailand. Drug resistance in cancer is a significant obstacle to the success of chemotherapy in cancer. There are several researches indicate the potential of herb in the inhibition of cancer cell proliferation for applying in cancer treatment.
Objectives: To study anti-proliferative activity of Samor Pipek (Terminalia bellirica (Gaertn.) Roxb.) fruit extracts against drug-sensitive and drug-resistant erythroleukemic cells.
Materials and methods: Samor Pipek fruits were extracted with acetonitrile, ethanol, and water. Anti-proliferative activity on drug-sensitive and drug-resistant erythroleukemic cells were determined by flow cytometer.
Results: Concentration of acetonitrile, ethanol and water extracts for inhibiting drug-sensitive erythroleukemic cell proliferation by 50% (IC50) were 24.70±8.05 μg/mL, 24.02±2.51 μg/mL and 13.09±3.40 μg/mL, respectively. IC50 of acetonitrile, ethanol and water extracts to inhibit drug- resistant erythroleukemic cell proliferation were 13.95±2.50 μg/mL, 20.45±10.10 μg/mL and 27.39±7.16 μg/mL, respectively. The resistance values of acetonitrile, ethanol and water extracts were 0.56, 0.85 and 2.09, respectively.
Conclusion: Acetonitrile, ethanol and water extracts could inhibit drug-sensitive and drug-resistant erythroleukemic cell proliferation in μg/mL range.
Journal of Associated Medical Sciences 2017; 50(1): 64-70. Doi: 10.14456/jams.2017.6
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Personal views expressed by the contributors in their articles are not necessarily those of the Journal of Associated Medical Sciences, Faculty of Associated Medical Sciences, Chiang Mai University.
References
2. Wu C-P, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies. Curr Mol Pharmacol 2008; 1(2): 93-105.
3. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008; 65: 3145-67.
4. Mankhetkorn S, Garnier-Suillerot A. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake. Eur J Pharmacol 1998; 343(2-3): 313-21.
5. Reungpatthanaphong P, Dechsupa S, Meesungnoen J, Loetchutinat C, Mankhetkorn S. Rhodamine B as a mitochondrial probe for measurement and monitoring of mitochondrial membrane potential in drug-sensitive and -resistant cells.J Biochem Biophys Methods 2003; 57(1): 1-16.
6. Meesungnoen J, Jay-Gerin JP, Mankhetkorn S. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines. Can J Physiol Pharmacol 2002; 80(11): 1054-63.
7. Slater L, Sweet P, Wetzel M, Stupecky M, Osann K. Comparison of cyclosporine A, verapamil,PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. Leuk Res 1995; 19: 5438.
8. B-artlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994; 12: 835-42.
9. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJ, Eeltink C, Vermorken JB,Pinedo HM. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997; 3: 2005-15.
10. Dantzig AH, Law KL, Cao J, Starling JJ. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 2001; 8: 39-50.
11. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM,Schellens JH. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002; 20: 2943-50.
12. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 1999; 128: 403-11.
13. Suttana W, Dechsupa N, Mankhetkorn S. Preparation of Maprang Seed Extracts and Evaluation of Their Anti-Proliferative Activity against Drug-Sensitive and Drug-Resistant Leukemic and Lung Cancer Cells. Srinagarind Med J 2013; 28:100-9. (in Thai)
14. Sabu MC, Kuttan R. Antidiabetic and antioxidant activity of Terminalia belerica Roxb. Indian J Exp Biol 2009; 47: 270-5.
15. Aqil F, Ahmad I. Antibacterial properties of traditionally used Indian medicinal plants. Method Find Exp Clin 2007; 29: 79-92.
16. Hazra B, Sarkar R, Biswas S, Mandal N. Comparative study of the antioxidant and reactive oxygen species scavenging properties in the extracts of the fruits of Terminalia chebula, Terminalia belerica and Emblica officinalis. BMC Complement Altern Med 2010; 10: 20.
17. Kaur S, Michael H, Arora S, Harkonen PL, Kumar S. The in vitro cytotoxic and apoptotic activity of Triphala—an Indian herbal drug. J Ethnopharmacol 2005; 97: 15-20.
18. Kumudhavalli MV, Vyas M, Jayakar B. Phytochemical and pharmacological evaluation of the plant fruit of Terminalia belerica Roxb. Int J Pharm Life Sci 2010; 1: 1-11.
19. Meshram G, Patil B, Shinde D, Metangale G. Effect of Epigallocatechin gallate isolated from Terminalia bellerica fruit rind on glucoamylase activity in vitro. J Appl Pharm Sci 2011; 1: 115-7.
20. Ghate NB, Hazra B, Sarkar R, Chaudhuri D, Mandal N. Alteration of Bax/Bcl-2 ratio contributes to Terminalia belerica-induced apoptosis in human lung and breast carcinoma. In Vitro Cell Dev Biol—Animal 2014; 50: 527-37.